

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KINGWORLD MEDICINES GROUP LIMITED**  
**金活醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code : 01110)

**(1) GRANT OF AWARD PURSUANT TO THE SHARE AWARD SCHEME  
AND  
(2) EXEMPTED CONNECTED TRANSACTION —  
GRANT OF AWARD TO CONNECTED PERSONS**

This announcement is made by Kingworld Medicines Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Chapter 14A and Rules 17.06A, 17.06B and 17.06C of the Listing Rules.

Reference is made to (i) the announcement of the Company dated 27 August 2019 in relation to the adoption of the Share Award Scheme by the Company (the “**Announcement**”), (ii) the announcements of the Company dated 22 May 2020 and 13 July 2022 in relation to the increase of scheme limit and (iii) the announcement of the Company dated 21 January 2022 in relation to the grant of award pursuant to the Share Award Scheme (the “**First Grant of Award**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

**GRANT OF AWARD PURSUANT TO SHARE AWARD SCHEME**

Further to the First Grant of Award, on 6 April 2023, the Board approved to grant the Award with an aggregate of 3,504,000 Awarded Shares to 79 Selected Participants under the Share Award Scheme adopted by the Company on 27 August 2019 at nil consideration, among which 1,044,000 Awarded Shares were granted to 14 Selected Participants who are Connected Grantees and 2,460,000 Awarded Shares were granted to 65 Selected Participants who are Non-connected Grantees (the “**Second Grant of Award**”).

For the Second Grant of Award, the Awarded Shares represent approximately 0.56% of the total issued share capital of the Company as at the Date of Grant (being 622,500,000 Shares). The closing price of the Shares on the Date of Grant was HK\$0.740 per Share and the average closing price of the Share for the five business days immediately preceding the Date of Grant was HK\$0.624 per Share.

Subject to the acceptance by the Grantees, the Awarded Shares shall be vested in the Grantees on 6 April 2023.

## **IMPLICATIONS UNDER THE LISTING RULES**

The Share Award Scheme was adopted before the effective date (being 1 January 2023) of the new Chapter 17 of the Listing Rules. The Company will comply with the new Chapter 17 in accordance with the transitional arrangement provided for the existing share schemes. The grant of the Awarded Shares to the Selected Participants has been approved by the Administration Committee of the Share Award Scheme, the Remuneration Committee of the Company and the Board (including the independent non-executive Directors), except that the relevant Director(s) and/or members of the respective committees to whom the grant was related had abstained from approving the grant to him/her.

Under the Second Grant of Award, the grant of the Awarded Shares to 14 Grantees who are Connected Persons of the Company constitutes connected transaction of the Company under Chapter 14A of the Listing Rules. As all the applicable percentage ratios are less than 0.1% and the grant is on normal commercial terms, each grant of the Awarded Shares to the Connected Persons of the Company is fully exempt from the reporting, announcement and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

Reference is made to (i) the announcement of the Company dated 27 August 2019 in relation to the adoption of the Share Award Scheme by the Company, (ii) the announcements of the Company dated 22 May 2020 and 13 July 2022 in relation to the increase of scheme limit and (iii) the announcement of the Company dated 21 January 2022 in relation to the First Grant of Award.

## **GRANT OF AWARD PURSUANT TO SHARE AWARD SCHEME**

On 6 April 2023 (the “**Date of Grant**”), the Board approved to grant the Award with an aggregate of 3,504,000 awarded shares (the “**Awarded Shares**”) to 79 Selected Participants (the “**Grantees**”) under the Share Award Scheme at nil consideration, among which, 1,044,000 Awarded Shares were granted to 14 Selected Participants who are Connected Persons of the Company (the “**Connected Grantees**”) and 2,460,000 Awarded Shares were granted to 65 Selected Participants who are not Connected Persons of the Company (the “**Non-connected Grantees**”).

For the Second Grant of Award, the Awarded Shares represent approximately 0.56% of the total issued share capital of the Company as at the Date of Grant (being 622,500,000 Shares). The closing price of the Shares on the Date of Grant was HK\$0.740 per Share and the average closing price of the Share for the five business days immediately preceding the Date of Grant was HK\$0.624 per Share.

The number of the Awarded Shares granted to each Grantee is determined after taking into account, among others, the Grantees' positions, performance and contribution to the Group. The nil consideration of the Awarded Shares is determined after taking into account, among others, the past contribution made by the Grantees to the Group.

The Awards granted are subject to the acceptance by the Grantees within the time as stipulated in the grant letter issued by the Company to the Grantees.

Subject to the acceptance by the Grantees, the Awarded Shares shall be vested in the Grantees on 6 April 2023.

## Details of the Grant of Award

Date of Grant: 6 April 2023

Aggregate number of underlying Shares in respect of Awarded Shares granted: 3,504,000

Out of the 3,504,000 Awarded Shares granted, 1,044,000 Awarded Shares were granted to 14 Connected Grantees, details of which are as follows:

		Number of Awarded Shares granted	Approximate percentage among the total Awarded Shares (%) (Note 1)	Approximate percentage of the total number of issued Shares as at the date of this announcement (%) (Note 2)
<b>Connected Grantees</b>				
<b>Zhao Li Sheng</b>	Chairman and Executive Director of the Company, controlling shareholder of the Company	156,000	4.45	0.03
<b>Chan Lok San</b>	Executive Director of the Company, controlling shareholder of the Company	132,000	3.77	0.02
<b>Zhou Xuhua</b>	Executive Director of the Company	88,000	2.51	0.01
<b>Zhang Jianbin</b>	Independent Non-executive Director	72,000	2.05	0.01
<b>Duan Jidong</b>	Independent Non-executive Director	72,000	2.05	0.01
<b>Wong Cheuk Lam</b>	Independent Non-executive Director	72,000	2.05	0.01
<b>Zhou Xiaoling</b>	Director of a subsidiary of the Company	120,000	3.42	0.02
<b>Chan Hon Wan</b>	Director of a subsidiary of the Company	72,000	2.05	0.01
<b>Zhao Jianwei</b>	Director of a subsidiary of the Company	52,000	1.48	0.01
<b>Zhao Weiyong</b>	Director of a subsidiary of the Company	52,000	1.48	0.01
<b>Niu Yaobin</b>	Director of a subsidiary of the Company	52,000	1.48	0.01
<b>Ma Shipeng</b>	Director of a subsidiary of the Company	52,000	1.48	0.01
<b>Huang Ruozhong</b>	Director of a subsidiary of the Company	32,000	0.91	0.01
<b>Li Enming</b>	Director of a subsidiary of the Company	20,000	0.56	0.00
<b>Sub-total</b>		1,044,000	29.79	0.17
<b>Non-connected Grantees</b>				
65 employees of the Group		2,460,000	70.21	0.40
<b>Total</b>		3,504,000	100.00	0.56

Purchase price of Awarded Shares granted:	HK\$0.385-1.060 per Share
Closing Price of the Shares on the Date of Grant:	HK\$0.740 per Share
Vesting Date ( <i>Note 3</i> ):	6 April 2023
Performance Targets of the Second Grant of Award:	There is no performance target attached to the Second Grant of Award. ( <i>Note 4</i> )
Clawback Mechanism:	There is no clawback mechanism attached to the Second Grant of Award. ( <i>Note 4</i> )

*Note 1:* The percentage figures are rounded to two decimal places.

*Note 2:* The percentage figures are rounded to two decimal places and calculated on the basis that there are 622,500,000 Shares in issue as at the date of this announcement.

*Note 3:* The vesting of the Awarded Shares to the Grantees is shorter than 12 months because the grant of the Share Awards was determined based on the Grantee's work performance in the financial year ended 31 December 2022 such as sales target, sales amount and/or sales completion rate, etc. As at the date of this announcement, there are no restrictions under the Scheme in respect of a vesting period of less than 12 months. The Board and the Remuneration Committee of the Company are of the view that such arrangement with a shorter vesting period is appropriate and aligns with the purpose of the Scheme.

*Note 4:* The purposes of the Share Award Scheme are to recognise the past contributions made by the Selected Participants and to provide incentives in retaining the Selected Participants for continual operation and development of the Group and to attract suitable personnel for further development of the Group through the grant of share awards to the Selected Participants. Having considered that (i) the Grantees are employees of the Group who contribute directly to the overall business performance of the Group, and (ii) the grant of Awarded Shares to the Grantees is a recognition of their respective past contributions to the Group, the Remuneration Committee of the Company considers that, even though there is no performance target nor clawback mechanism attached to the Second Grant of Award, the grant of Awarded Shares to the Connected Grantees and the Non-connected Grantees can align the interests and incentives of the Grantees in working towards the successes of the Group, and reinforce their commitment to long term services within the Group, which is in line with the purpose of the Share Award Scheme.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, save as disclosed above, each of the Non-connected Grantees is an employee of the Group and not a Connected Person.

The Awarded Shares, being Shares purchased on the open market, are held on trust for the Grantees by the Trustee pursuant to the Trust Deed. The Trustee shall transfer the Awarded Shares to the Grantees in accordance with the Award Scheme Rules.

The Second Grant of Award as detailed above had been approved by the Administration Committee of the Share Award Scheme, the Remuneration Committee and the Board (including the independent non-executive Directors), except that the relevant Director(s) and/or members of the respective committees to whom the grant was related had abstained from approving the grant to him/her.

## **REASONS FOR AND BENEFITS OF THE GRANT OF AWARD**

The purposes of the Share Award Scheme are to recognise the contributions by certain Participants and to provide incentives in retaining the Participants for the continual operation and development of the Group and to attract suitable personnel for further development of the Group.

On the basis that (i) the Award to the Grantees aims to recognise their past contribution to the Group and encourage them to make continual contribution to the Group; and (ii) save for the 1,556,000 Awarded Shares under the First Grant of Award and the 3,504,000 Awarded Shares under the Second Grant of Award, the Company has not granted any award under the Share Award Scheme as at the date of this announcement, the Directors (including the independent non-executive Directors) consider that the Second Grant of Award provided to the Grantees conforms to the current situation and development of the Group and is necessary and reasonable.

The Directors (including the independent non-executive Directors) are of the view that the Second Grant of Award to the Grantees, the respective terms and the transactions contemplated thereunder are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

## **NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT**

As of the date of this announcement, the 3,504,000 Shares underlying the Second Grant of Award to the Selected Participants were directly held by the Trustee, so no new Shares are required to be issued by the Company pursuant to the Second Grant of Award. Accordingly, the Second Grant of Award will not result in any dilution effect to the number of total issued Shares upon vesting thereof.

After the granting of the Second Grant of Award, a total of 40,940,000 Shares will be available for future grant pursuant to the Share Award Scheme. Except from the Awarded Shares, the Trustee holds 27,236,000 Shares on trust for the Share Award Scheme as at the date of this announcement which will be available for future grant pursuant to the Share Award Scheme.

## **LISTING RULES IMPLICATIONS**

The Share Award Scheme was adopted before the effective date (being 1 January 2023) of the new Chapter 17 of the Listing Rules. The Company will comply with the new Chapter 17 in accordance with the transitional arrangement provided for the existing share schemes. The grant of the Awarded Shares to the Selected Participants has been approved by the Administration Committee of the Share Award Scheme, the Remuneration Committee of the Company and the Board (including the independent non-executive Directors), except that the relevant Director(s) and/or members of the respective Committees to whom the grant was related had abstained from approving the grant to him/her.

Under the Second Grant of Award, the grant of the Awarded Shares to 14 Grantees who are Connected Persons of the Company constitutes connected transaction of the Company under Chapter 14A of the Listing Rules. As all the applicable percentage ratios are less than 0.1% and the grant is on normal commercial terms, each grant of the Awarded Shares to the Connected Persons of the Company is fully exempt from the reporting, announcement and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

By order of the Board  
**Kingworld Medicines Group Limited**  
**Zhao Li Sheng**  
*Chairman*

Hong Kong, 6 April 2023

*As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.*